Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
Level 5 - mechanism / opinion, no new human data
Narrative review and protocol framework proposal without new clinical trial data
PubMed 39639257 · doi:10.1186/s12916-024-03775-4
What was done
The authors synthesized mechanistic evidence on glioblastoma energy requirements (specifically dependency on glucose and glutamine) to propose a standardized clinical research framework and consensus treatment protocol for ketogenic metabolic therapy (KMT). The proposed protocol incorporates glucose-ketone index (GKI) monitoring, ketogenic diets, fasting, calorie restriction, and metabolic inhibitors targeting glycolysis and glutaminolysis.
What was found
The abstract outlines a conceptual treatment and research framework rather than empirical results. No quantitative clinical data, patient sample sizes, or survival metrics are reported.
Why it matters
It provides a standardized methodological and biomarker framework to align future observational and interventional trials evaluating metabolic diet-drug combinations in glioblastoma.
Limits
The abstract describes a theoretical framework and consensus proposal without presenting original human trial data, safety outcomes, or survival statistics. Clinical feasibility, patient adherence to intensive dietary regimens, and actual in vivo efficacy in human glioblastoma remain to be demonstrated in prospective trials.
Cited by
- context A paper published in Frontiers in Science demonstrates that the Glucose Ketone Index (GKI) can be used as a management tool across all major chronic diseases and cancers.
- context Maintaining a low Glucose-Ketone Index (GKI) reduces the required effective dose of oncology drugs by half.